Clinical Trials Directory

Trials / Terminated

TerminatedNCT02905643

Discerning Pseudoprogression vs True Tumor Growth in GBMs

The Use of Peak Height and Percentage Signal Recovery for Evaluation and Determination of Pseudoprogression in Glioblastoma Patients

Status
Terminated
Phase
Study type
Observational
Enrollment
1 (actual)
Sponsor
Ascension Health · Industry
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

One-third of all primary brain tumors are astrocytomas, the most common type of glioma. Grade 4 astrocytomas, more commonly known as glioblastomas (GBMs), represent about 50% of all gliomas (annual incidence of over 3 per 100,000) and are associated with high mortality rates and median patient survival of just 12-15 months post-diagnosis. Treatment response is assessed by measuring post-treatment tumor size on contrast-enhanced magnetic resonance images (MRI). However, radiation and chemotherapy cause inflammatory and necrotic changes which, like actual tumor progression itself, demonstrate contrast enhancement on the first post-treatment MRI scan. This enhancement eventually subsides (typically within 6 months of treatment) and is known as pseudoprogression (PsP). Currently, there is no gold standard noninvasive tool for distinguishing between pseudoprogression and progressive disease. Dynamic susceptibility-weighted contrast-enhanced perfusion MRI (DSC perfusion MRI) permits measurement of hemodynamic imaging variables. Previous literature reports attempted to use some or all of these metrics to assess their utility in distinguishing PsP from true cancer progression. These studies showed mixed results, likely due to a number of factors, including poor statistical power, poorly defined PsP, analysis of multiple cancer grades and types, and varied analysis methodologies. The investigators aim to address these issues in this study.

Detailed description

See BRIEF SUMMARY section

Conditions

Interventions

TypeNameDescription
OTHERStudy subjectsThis study does not include an intervention it is only observational.

Timeline

Start date
2016-09-01
Primary completion
2018-02-13
Completion
2018-02-13
First posted
2016-09-19
Last updated
2024-02-22

Source: ClinicalTrials.gov record NCT02905643. Inclusion in this directory is not an endorsement.